Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAKHRAVAC (MIVAC) 10 microgram phase 2 safety and immunogenicity trial
IRCT20210206050259N2Phase 2Completed
- Sponsor
- Organization of Defensive Innovation and Research
- Start
- Jun 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing FAKHRAVAC 10 microgram with Placebo (2 arms). Primary endpoints: Reactogenicity and early safety and Humoral immunogenicity. Started Jun 2021; status: completed.
02
Drugs
FINCoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210206050259N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210206050259N2.